Drug intelligence / Profile preview

BPM-RSV-001

Development stage: Preclinical
Lead developer: Baiya Phytopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BPM-RSV-001 is a neutralizing monoclonal antibody developed by Baiya Phytopharm for the prevention and treatment of Respiratory Syncytial Virus (RSV) infection. The antibody targets the RSV Fusion (F) protein, which is essential for the virus to fuse with and enter host cells. By binding to this protein, BPM-RSV-001 neutralizes the virus and prevents the progression of infection. As of 2024, the candidate is in preclinical development and is produced using Baiya Phytopharm's proprietary plant-based expression platform.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on BPM-RSV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM-RSV-001.

Explore the full profile